Latino Semaglutide Study

Inclusion Criteria:

• Self-identify as being of Hispanic/Latino ethnicity

• BMI >30

• Age 18-75 years old

• Able to provide informed consent before any trial related activities

Exclusion Criteria:

• Current cancer treatment

• Diabetes, Type 1 or Type 2

• Eating disorders

• Medication use targeting the GPL-1 system

• In the last 30 days, attempted to lose weight by lifestyle modification alone orwith the use of anti-obesity medications resulting in more than 5 pounds of weightloss.

• History of bariatric surgery

• Use of obesogenic medications (including but not limited to steroids, haloperidol,clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, andlithium) which cannot be substituted or stopped.

• Pregnant or planning to become pregnant in the next 8 months

• Genetic disorders and/or physical or mental handicaps that would limit participationin the study and/or the intensive lifestyle intervention.

• Any contraindication to semaglutide 2.4 mg including personal or family history ofmedullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2,hypersensitivity to semaglutide 2.4 mg or any product components.

• Any known or suspected allergy to semaglutide 2.4 mg or related products

• Previous participation in this trial, either initial screening or grouprandomization